Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients - 21/06/19
Abstract |
Background |
Bullous pemphigoid (BP) is the most common autoimmune blistering disease requiring treatment with immunosuppressive medications; however, finding a therapy that has a sustained durable response and an acceptable side effect profile has been challenging.
Objective |
Our study aimed to evaluate the clinical outcomes of patients with BP treated with rituximab therapy at a single academic center.
Methods |
A retrospective chart review was performed on 20 patients who received at least 1 dose of rituximab therapy, either as initial therapy for severe BP or as therapy for recalcitrant disease after having failed conventional immunotherapies.
Results |
Within our cohort, 75% of patients (n = 15) achieved remission an average of 169 days following rituximab therapy. There were no rituximab-related deaths and significantly fewer adverse events following rituximab therapy.
Limitations |
This study was limited by its retrospective nature, focus on a single academic center, and small sample size.
Conclusion |
Use of rituximab therapy demonstrated high rates of remission, steroid-sparing activity, and an acceptable safety profile in our cohort of patients with severe BP or disease refractory to conventional therapies.
Le texte complet de cet article est disponible en PDF.Key words : autoimmune blistering disease, bullous pemphigoid, relapse, remission, rituximab
Abbreviations used : BP, BPDAI, IR, RA
Plan
| Drs Polansky and Eisenstadt are cofirst authors. |
|
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
Vol 81 - N° 1
P. 179-186 - juillet 2019 Retour au numéro
Article précédent
- Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
- Alexander Egeberg, Lars Erik Bryld, Lone Skov
- Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom
- Laurent Eckert, Shaloo Gupta, Abhijit Gadkari, Puneet Mahajan, Joel M. Gelfand
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?